Abbott Laboratories (ABT)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 47,664,000 | 38,603,000 | 36,686,000 | 35,802,000 | 32,784,000 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $47,664,000K
= 0.00
The debt-to-equity ratio for Abbott Laboratories has consistently remained at 0.00 from December 31, 2020 to December 31, 2024. This indicates that the company has either no debt or a very minimal amount of debt relative to its equity. A debt-to-equity ratio of 0.00 suggests that Abbott Laboratories relies primarily on its equity financing to support its operations and growth rather than taking on debt. This can be seen as a positive sign of financial stability and strength, as it means the company has a lower risk of financial distress associated with high debt levels. However, it is important to note that a very low debt-to-equity ratio may also indicate that the company is not taking full advantage of debt financing, which could potentially limit its growth opportunities. Overall, Abbott Laboratories' consistent 0.00 debt-to-equity ratio over the years reflects a conservative approach to capital structure management.
Peer comparison
Dec 31, 2024